CN116783183B - 用于治疗贫血和癌症的vhl抑制剂 - Google Patents

用于治疗贫血和癌症的vhl抑制剂

Info

Publication number
CN116783183B
CN116783183B CN202080108318.5A CN202080108318A CN116783183B CN 116783183 B CN116783183 B CN 116783183B CN 202080108318 A CN202080108318 A CN 202080108318A CN 116783183 B CN116783183 B CN 116783183B
Authority
CN
China
Prior art keywords
independently
alkyl
compound
group
foregoing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080108318.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN116783183A (zh
Inventor
J·福尔曼
吴昊
W·J·费尔布拉泽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CN116783183A publication Critical patent/CN116783183A/zh
Application granted granted Critical
Publication of CN116783183B publication Critical patent/CN116783183B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080108318.5A 2020-11-11 2020-11-30 用于治疗贫血和癌症的vhl抑制剂 Active CN116783183B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063112609P 2020-11-11 2020-11-11
US63/112,609 2020-11-11
PCT/US2020/062627 WO2022103411A1 (en) 2020-11-11 2020-11-30 1-(2-(4-cyclopropyl-1h-1,2,3-triazol-1-yl)acetyl)-4-hydroxy-n-(benzyl)pyrrolidin e-2-carboxamide derivatives as vhl inhibitors for the treatment of anemia and cancer

Publications (2)

Publication Number Publication Date
CN116783183A CN116783183A (zh) 2023-09-19
CN116783183B true CN116783183B (zh) 2026-03-20

Family

ID=73839136

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080108318.5A Active CN116783183B (zh) 2020-11-11 2020-11-30 用于治疗贫血和癌症的vhl抑制剂

Country Status (10)

Country Link
US (1) US20230391766A1 (https=)
EP (1) EP4244218A1 (https=)
JP (2) JP7654075B2 (https=)
KR (1) KR20230106637A (https=)
CN (1) CN116783183B (https=)
AU (1) AU2020476996A1 (https=)
CA (1) CA3197092A1 (https=)
IL (1) IL302678A (https=)
MX (1) MX2023005305A (https=)
WO (1) WO2022103411A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119677735A (zh) * 2022-05-11 2025-03-21 基因泰克公司 作为vhl配体的苯并噻唑化合物
WO2025162250A1 (zh) * 2024-02-04 2025-08-07 贝达药业股份有限公司 取代的三环化合物及其用途
WO2025228305A1 (zh) * 2024-04-28 2025-11-06 中国科学院上海药物研究所 一种蛋白降解剂缀合物及其偶联物
WO2026012475A1 (en) * 2024-07-12 2026-01-15 Ascentage Pharma (Suzhou) Co., Ltd. Vhl ligands and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109952299A (zh) * 2016-09-14 2019-06-28 邓迪大学 用于制备蛋白降解靶向嵌合体的氟代羟脯氨酸衍生物
CN110573507A (zh) * 2017-04-14 2019-12-13 邓迪大学 小分子

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
WO2013106646A2 (en) * 2012-01-12 2013-07-18 Yale University Compounds and methods for the inhibition of vcb e3 ubiquitin ligase
KR102668696B1 (ko) * 2012-01-12 2024-05-29 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
US11547759B2 (en) * 2019-01-30 2023-01-10 Montelino Therapeutics, Inc. Bi-functional compounds and methods for targeted ubiquitination of androgen receptor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109952299A (zh) * 2016-09-14 2019-06-28 邓迪大学 用于制备蛋白降解靶向嵌合体的氟代羟脯氨酸衍生物
CN110573507A (zh) * 2017-04-14 2019-12-13 邓迪大学 小分子

Also Published As

Publication number Publication date
MX2023005305A (es) 2023-05-25
WO2022103411A1 (en) 2022-05-19
US20230391766A1 (en) 2023-12-07
KR20230106637A (ko) 2023-07-13
AU2020476996A1 (en) 2023-06-29
CN116783183A (zh) 2023-09-19
CA3197092A1 (en) 2022-05-19
JP7654075B2 (ja) 2025-03-31
IL302678A (en) 2023-07-01
JP2023549187A (ja) 2023-11-22
EP4244218A1 (en) 2023-09-20
JP2025063287A (ja) 2025-04-15

Similar Documents

Publication Publication Date Title
CN111153901B (zh) 一类含氮稠杂环类shp2抑制剂化合物、制备方法和用途
CN116783183B (zh) 用于治疗贫血和癌症的vhl抑制剂
CN107698569B (zh) 作为jak抑制剂的联吡唑衍生物
JP2022527298A (ja) Ｓｔａｔ３の低分子分解誘導剤
JP2020527577A (ja) Ｔｌｒ７／８アンタゴニストおよびそれらの使用
CN112236429A (zh) 用作ii型irak抑制剂的杂芳基化合物及其用途
JP2019537588A (ja) 神経栄養因子チロシンキナーゼ受容体阻害剤として用いられるアミノピラゾロピリミジン化合物
EP4353724A1 (en) Compound as cdk kinase inhibitor and use thereof
JP2022538901A (ja) ピラゾロン縮合ピリミジン化合物、その製造方法及び使用
JP2026507476A (ja) トリフルオロメタンスルホニル基を含む化合物
WO2018028491A1 (zh) 吲哚胺2，3-双加氧酶抑制剂及其在药学中的用途
WO2022171072A1 (zh) 一种二氢嘧啶类化合物、其制备方法及其应用
WO2021129841A1 (zh) 用作ret激酶抑制剂的化合物及其应用
JP7834099B2 (ja) 貧血の処置のためのｖｈｌ阻害剤としての１－（２－（４－シクロプロピル－１ｈ－１，２，３－トリアゾール－１－イル）アセチル）－４－ヒドロキシピロリジン－２－カルボキサミド誘導体
CN119677735A (zh) 作为vhl配体的苯并噻唑化合物
HK40092810A (zh) 作为vhl抑制剂用於治疗贫血和癌症的1-(2-(4-环丙基-1h-1，2，3-三唑-1-基)乙酰基)-4-羟基-n-(苄基)吡咯烷-2-甲酰胺衍生物
CN116507617A (zh) 作为vhl抑制剂用于治疗贫血的1-(2-(4-环丙基-1h-1,2,3-三唑-1-基)乙酰基)-4-羟基吡咯烷-2-甲酰胺衍生物
HK40095494A (zh) 作为vhl抑制剂用於治疗贫血的1-(2-(4-环丙基-1h-1，2，3-三唑-1-基)乙酰基)-4-羟基吡咯烷-2-甲酰胺衍生物
HK40029944B (en) Nitrogen-containing fused heterocyclic shp2 inhibitor compound, preparation method, and use
HK40029944A (en) Nitrogen-containing fused heterocyclic shp2 inhibitor compound, preparation method, and use
HK40043591B (zh) 用作ii型irak抑制剂的杂芳基化合物及其用途
HK40043591A (en) Heteroaryl compounds as type ii irak inhibitors and uses thereof
HK1246287A1 (zh) 用作irak抑制剂的哒嗪酮类大环化合物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40092810

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant